Equities

Indivior PLC

INDV:LSE

Indivior PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)743.50
  • Today's Change30.00 / 4.20%
  • Shares traded569.82k
  • 1 Year change-57.76%
  • Beta-0.1273
Data delayed at least 20 minutes, as of Sep 27 2024 16:52 BST.
More ▼

Forecasts data is unavailable for this security.

Consensus recommendation

  • 19-Oct-23
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
  • 26-Sep-24
Select bar for recommendation details.
Recommendations26-Sep-24
Buy1
Outperform3
Hold0
Sell0
Strong Sell0

Share price forecast

The 4 analysts offering 12 month price targets for Indivior PLC have a median target of 1,843.06, with a high estimate of 2,092.04 and a low estimate of 1,493.88. The median estimate represents a 147.89% increase from the last price of 743.50.
High181.4%2,092.04
Med147.9%1,843.06
Low100.9%1,493.88

Earnings history & estimates

On Nov 09, 2023, earnings of 0.34 per share.
The next earnings announcement is expected on Feb 19, 2025.
Average growth rate+50.34%
Indivior PLC reported annual 2023 earnings of 1.57 per share on Feb 22, 2024.
Average growth rate+31.00%
More ▼

Revenue history & estimates

of 293.00m.
Average growth rate+5.09%
Indivior PLC had revenues for the full year 2023 of 1.09bn. This was 21.31% above the prior year's results.
Average growth rate+9.97%
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.